139 related articles for article (PubMed ID: 19232881)
21. The influence of (18)flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma.
Smith JW; Moreira J; Abood G; Aranha GV; Nagda S; Wagner RH; Shoup M
Am J Surg; 2009 Mar; 197(3):308-12. PubMed ID: 19245906
[TBL] [Abstract][Full Text] [Related]
22. Interim
Cremonesi M; Garibaldi C; Timmerman R; Ferrari M; Ronchi S; Grana CM; Travaini L; Gilardi L; Starzyńska A; Ciardo D; Orecchia R; Jereczek-Fossa BA; Leonardi MC
Radiother Oncol; 2017 Nov; 125(2):200-212. PubMed ID: 29029833
[TBL] [Abstract][Full Text] [Related]
23. Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review.
Wong WL; Chambers RJ
Abdom Imaging; 2008; 33(2):183-90. PubMed ID: 17619927
[TBL] [Abstract][Full Text] [Related]
24. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
[TBL] [Abstract][Full Text] [Related]
26. Novel 5-point 18-FDG-PET/CT visual scoring system for assessing treatment response in patients with oesophageal or gastro-oesophageal junction carcinoma.
Cong E; Oar AJ; Lee MT; Chicco A; Lin M; Yap J; Lin P; Ho Shon I
J Med Imaging Radiat Oncol; 2021 Feb; 65(1):23-37. PubMed ID: 33063470
[TBL] [Abstract][Full Text] [Related]
27. Role of FDG-PET scan in staging of cancer of the esophagus and gastroesophageal junction.
Lerut T; Flamen P
Minerva Chir; 2002 Dec; 57(6):837-45. PubMed ID: 12592225
[TBL] [Abstract][Full Text] [Related]
28. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
29. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
[TBL] [Abstract][Full Text] [Related]
30. F-18-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer.
Schmidt M; Bollschweiler E; Hölscher A
Ann Surg; 2010 Aug; 252(2):412-3; author reply 413. PubMed ID: 20647915
[No Abstract] [Full Text] [Related]
31. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
Song SY; Kim JH; Ryu JS; Lee GH; Kim SB; Park SI; Song HY; Cho KJ; Ahn SD; Lee SW; Shin SS; Choi EK
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1053-9. PubMed ID: 15964705
[TBL] [Abstract][Full Text] [Related]
32. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Strategies for Esophageal Cancer: Role of Immunotherapy and Positron emission tomography (PET)-Guided Strategies.
Barron CC; Wang X; Elimova E
Thorac Surg Clin; 2023 May; 33(2):197-208. PubMed ID: 37045489
[TBL] [Abstract][Full Text] [Related]
34. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
[TBL] [Abstract][Full Text] [Related]
35. Reassessment of patients with esophageal cancer after neoadjuvant therapy.
Das A; Chak A
Endoscopy; 2006 Jun; 38 Suppl 1():S13-7. PubMed ID: 16802216
[No Abstract] [Full Text] [Related]
36. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.
Elliott JA; O'Farrell NJ; King S; Halpenny D; Malik V; Muldoon C; Johnston C; Reynolds JV
Br J Surg; 2014 Dec; 101(13):1702-11. PubMed ID: 25351460
[TBL] [Abstract][Full Text] [Related]
37. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.
Avril N; Sassen S; Schmalfeldt B; Naehrig J; Rutke S; Weber WA; Werner M; Graeff H; Schwaiger M; Kuhn W
J Clin Oncol; 2005 Oct; 23(30):7445-53. PubMed ID: 16157939
[TBL] [Abstract][Full Text] [Related]
38. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma.
Makino T; Doki Y; Miyata H; Yasuda T; Yamasaki M; Fujiwara Y; Takiguchi S; Higuchi I; Hatazawa J; Monden M
Surgery; 2008 Nov; 144(5):793-802. PubMed ID: 19081023
[TBL] [Abstract][Full Text] [Related]
39. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
Chowdhury FU; Bradley KM; Gleeson FV
Clin Radiol; 2008 Dec; 63(12):1297-309. PubMed ID: 18996259
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
